|
Arecor Therapeutics PLC on Monday said revenue fell in 2025 due to the end of operations at Tetris Pharma. The Cambridgeshire, England-based biopharmaceutical company said revenue including discontinued operations fell 39% to £3.1 million in 2025 from £5.1 million in 2024. Revenue for continuing operations was £1.7 million, up 6.3% from £1.6 million a year prior. Continuing operations excludes Tertis Pharma, which ended operations in September 2025. In a trading update, the company said it continues to focus on the core product areas of diabetes and oral delivery of peptides. Arecor said cash and cash equivalents at the end of the year was 91% higher at £6.1 million compared to £3.2 million at the end of 2024. This was above expectations mostly due to favourable performance at Testris, Arecor added. ‘During 2025, we focused our strategy on two core product areas, AT278 for diabetes and the oral delivery of peptides, both of which are high growth multi-billion-dollar markets where our technology gives us an edge,’ said Chief Executive Officer Sarah Howell. ‘We are also continuing to generate insights and data to inform next development steps for our oral peptide delivery platform, which has a low resource burden but a large commercial upside opportunity. These developments are supported by a solid financial position.’ Shares in Arecor Therapeutics were down 0.1% at 77.40 pence on Monday afternoon in London. Copyright 2026 Alliance News Ltd. All Rights Reserved.
|
